Case report

http://dx.doi.org/10.3345/kjp.2011.54.9.385
Korean J Pediatr 2011;54(9):385-388

Candida tropicalis arthritis of the elbow in a patient with Ewing's sarcoma that successfully responded to itraconazole

Seung Youn Kim, MD, Jung Sub Lim, MD, Dong Hwan Kim, MD, Hyeon Jeong Lee, MD, Joong Bum Cho, MD, Jun Ah Lee, MD, Dong Ho Kim, MD

Department of Pediatrics, Korean Cancer Center Hospital, Seoul, Korea

Received: 25 March 2011, Revised: 21 April 2011
Accepted: 13 June 2011
Corresponding author: Dong Ho Kim, MD
Department of Pediatrics, Korean Cancer Center Hospital, 215-4 Gongneung-dong, Nowon-gu, Seoul 139-706, Korea
Tel: +82-2-970-2894, Fax: +82-2-970-1970
E-mail: hearing7@paran.com

Copyright © 2011 by The Korean Pediatric Society

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Candida arthritis in patients with a malignancy is rare, especially in children. Nevertheless, a few cases of Candida arthritis have been reported in immunocompromised patients and neonates. Here, we report a patient with Ewing sarcoma who developed Candida tropicalis arthritis of the elbow during chemotherapy. An initial non-response to treatment with antibiotics in arthritis, particularly in neutropenic patients, should raise suspicion of a fungal infection like candidiasis. Although, amphotericin B is the first choice treatment for Candida infections, it has many side effects, such as electrolyte imbalance, and is only available in an intravenous form. However, fungal arthritis needs at least 3 months of therapy. On the other hand, itraconazole is available in intravenous and oral forms. We describe the successful treatment of a 13-year-old Ewing sarcoma patient with Candida arthritis using oral and intravenous itraconazole.

Case report

A 13-year-old boy presented with fever and not swollen discomfort of the right elbow without swelling and tenderness. Four months previously, he had been diagnosed to have Ewing sarcoma of the right ilium and had undergone five cycles of preoperative chemotherapy. He had contracted a C. tropicalis urinary tract infection during a febrile neutropenia episode after chemotherapy, which was treated with itraconazole and broad spectrum antibiotics for 7 days. No growth was reported in the last urine culture after itraconazole treatment. Recently, he had been on preoperative chemotherapy (vincristine, ifosfamide, doxorubicin, and etoposide), which he had...
At presentation, his body temperature was 37.5°C, pulse rate 120 per minute, respiration rate 20 per minute, and blood pressure 130/70 mmHg. Physical examination revealed a slight throat infection, but no sinus tenderness, nor tonsilar nor lymph node enlargement. Heart and lung sounds were normal, liver and spleen were non-palpable, and no edema or pain was found in the lower extremities. He complained of discomfort of the right elbow. Laboratory tests revealed pancytopenia, and complete blood count findings were leukocytes 160/mm$^3$, absolute neutrophil count 40/mm$^3$, hemoglobin 9.4 g/dL, and platelet count 8,000/mm$^3$. Broad-spectrum antibiotics (piperaclilin/tazobactam and isepacin) were immediately administered after obtaining blood and urine for culture studies.

After two days of antibiotic treatment, mild tenderness and swelling (without heating sensation) were detected on the right elbow. A simple radiograph obtained on the 3rd hospital day revealed soft tissue swelling with a positive fat pad sign (Fig. 1). Ultrasonography on the 4th hospital day showed soft tissue edema and articular effusion, and subsequently, 15 mL of yellowish fluid was aspirated from the joint and cultured (Fig. 2). A three phase bone scan (Fig. 3) performed on the 6th hospital day for the differential diagnosis of tumor metastasis and infection showed a limited region of uptake on the right elbow, suggesting the possibility of arthritis.

The symptoms and signs of arthritis aggravated despite a 10-day course of broad-spectrum antibiotics. On the 11th hospital day, cultures of synovial fluid and tissue demonstrated the presence of *C. tropicalis*. However, blood and urine culture specimens were negative. Follow-up right upper elbow ultrasonography on the 11th hospital day showed elbow articular space effusion and hypertrophic

---

**Fig. 1.** Lateral view of the right elbow shows soft tissue swelling with a positive fat pad sign (arrow head).

**Fig. 2.** Ultrasonograph of the right elbow shows joint effusion with lobular margined fluid collection of 3.4x1.2x3.6 cm and increased peripheral vascularity in the right anterior and posterior elbow joint and olecranon, and bicipital radial bursa.

**Fig. 3.** A 3-phase bone scan shows diffuse, elevated tracer uptake in the right elbow joint area on blood pool image and delayed images, suggestive of arthritis (A) and resolution of the lesion 4 months later (B).
synovium. Emergent decompression was performed on the same day, and a drain tube was placed in the right elbow articular space. During the operation, 2 mL of a yellowish-red turbid synovial fluid sample was obtained and submitted for culture, which later confirmed the presence of C. tropicalis. In addition, abdominal computed tomography on the same day showed no evidence of hepato-splenic candidiasis.

Intravenous itraconazole 400 mg/day (5 mg/kg/day) was started on the 11th and 12th days. Intravenous itraconazole was decreased to 200 mg/day on the 13th day and then kept at the same dose. Fever, joint swelling, and arthralgia gradually resolved after itraconazole treatment, and after 2 weeks of intravenous itraconazole treatment on the 25th hospital day. Intravenous itraconazole 200 mg/day was substituted for oral itraconazole solution at 200 mg/day.

The antifungal treatment was maintained for three months, and from 14 days after treatment commencement the patient had no elbow pain and was without disability. Furthermore, no relapse of the fungal arthritis occurred during oral itraconazole therapy. Simple radiography and an arthrocentesis carried out after 3 months of antifungal treatment showed no abnormal lesion related to septic arthritis, and oral itraconazole was discontinued.

**Discussion**

This is the first case report issued on Candida arthritis arising in a child with a solid tumor during chemotherapy in Korea. Previously, only three cases of arthritis have been reported in hematologic malignances in children. Although the exact pathogenesis of Candida arthritis in our case is unclear, it appears to have originated due to disturbed microbial flora levels in the host, and to have spread hematogenously from a previous Candida cystitis infection, since dissemination to a joint is possible by direct inoculation (surgery or intra-articular inoculation) or by hematogenous dissemination. In our case, the arthritis developed 2 weeks after a chemotherapy-induced granulocytopenic period in the absence of any invasive manipulation. Accordingly, hematogenous spread to the synovium of the elbow is believed to be the most likely cause.

Because joint infections (septic arthritis) are rare in the absence of trauma or surgery in children, it is difficult to suspect fungal arthritis in clinical settings. However, joint swelling or arthralgia after a recovery period in neutropenic fever patients should raise suspicion of fungal arthritis. This condition is associated with only mild pain and swelling with persisting low-grade fever. However, growth of the fungus in a synovial fluid culture provides a definite diagnosis. Although, some cases reported facts that synovial fluid in fungal arthritis appears as “yellow-green pus” or “as necrotic tissue”, color hardly distinguishes this condition from other types of septic arthritis.

A review of the literature revealed that Candida albicans and C. tropicalis are major pathogens in adult patients with a hematological malignancy (12 cases of acute leukemia, chronic myeloid leukemia, and small lymphocytic lymphoma), and the knee was the only affected joint in these patients.

Because of its rarity and a lack of experience, no consensus has been reached or guideline issued on the treatment of Candida arthritis. The objectives of treatment are to relieve symptoms, eradicate infection, and restore joint function. Usually, intravenous amphotericin B (0.5 to 1 mg/kg per day for 6 to 10 weeks) and oral or intravenous fluconazole (6 mg/kg per day for 6 to 12 months) have been used in conjunction with adequate drainage. Some cases have been treated with caspofungin, a newly developed antifungal agent. The described case was treated with itraconazole (at 5 mg/kg per day). Intravenous itraconazole was administered at 200 mg 12 hourly for 2 days, and then at 200 mg/day, based on evidence that this dosing regimen achieves adequate blood levels more rapidly with less patient-to-patient variability than oral preparations of the drug. Itraconazole is as effective as amphotericin B in some cases of disseminated Candida infection, and has advantages over amphotericin B for the treatment of granulocytopenia. In fact, the treatment of such infections with amphotericin B is difficult, because of its many side-effects, which include hypotension, fever, shivering, thrombophlebitis, nephrotoxicity, renal tubular acidosis, hypokalemia, anemia and thrombocytopenia. Thus, prolonged therapy with amphotericin B is difficult in a chemotherapy setting.

**References**

1. McCullers JA, Flynn PM. Candida tropicalis osteomyelitis: case report and review. Clin Infect Dis 1998;26:1000-1.
2. Sim JP, Kho BC, Liu HS, Yung R, Chan JC. Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin. Hong Kong Med J 2005;11:120-3.
3. Koo M, Kim D. The clinical aspects of septic arthritis in children. J Korean Pediatr Soc 1997;40:1737-44.
4. Fainstein V, Gilmore C, Hopfer RL, Maksymiuk A, Bodey GP. Septic arthritis due to Candida species on patients with cancer: report of five cases and review of the literature. Rev Infect Dis 1982;4:78-85.
5. Marra F, Robbins GM, Masri BA, Duncan C, Wasan KM, Kwong EH, et al. Amphotericin B-loaded bone cement to treat osteomyelitis caused by Candida albicans. Can J Surg 2001;44:383-6.
6. Ferra C, Doebbeling BN, Hollis RJ, Pfaffer MA, Lee CK, Gingrich RD. Candida tropicalis vertebral osteomyelitis: a late sequela of fungemia. Clin Infect Dis 1994;19:697-703.
7. Weigl JA. Candida arthritis in a premature infant treated successfully with oral fluconazole for six months. Ann Acad Med Singapore 2000;29:253-
5. Weers-Pothoff G, Havermans JF, Kamphuis J, Sinnige HA, Meis JF. Candida tropicalis arthritis in a patient with acute myeloid leukemia successfully treated with fluconazole: case report and review of the literature. Infection 1997;25:109-11.

9. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89.

10. Poplack DG, Jacobs SA. Candida arthritis treated with amphotericin B. J Pediatr 1975;87(6 Pt 1):989-90.

11. Bayer AS, Guze LB. Fungal arthritis. I. Candida arthritis: diagnostic and prognostic implications and therapeutic considerations. Semin Arthritis Rheum 1978;8:142-50.

12. Yang SC, Shao PL, Hsueh PR, Lin KH, Huang LM. Successful treatment of Candida tropicalis arthritis, osteomyelitis and costochondritis with caspofungin and fluconazole in a recipient of bone marrow transplantation. Acta Paediatr 2006;95:629-30.

13. Knoke M, Bernhardt H, Schulz K, Schröder G, Zimmermann K. Funguria and Candida-specific immunoglobulins in patients with systemic candidosis. Mycoses 2000;43:145-9.

14. Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2001;26:159-69.

15. van’t Wout JW. Itraconazole in neutropenic patients. Chemotherapy 1992;38 Suppl 1:23-6.